You are here

Article Text

Article menu

Download PDFPDF

Electronic pages
Correspondence
JAK inhibition in STING-associated interferonopathy
Free
  1. Mathieu P Rodero1,
  2. Marie-Louise Frémond1,
  3. Gillian I Rice2,
  4. Bénédicte Neven3,4,5,
  5. Yanick J Crow1,2
  1. 1Laboratory of Neurogenetics and Neuroinflammation, INSERM UMR1163, Institut Imagine, Paris, France
  2. 2Manchester Centre for Genomic Medicine, University of Manchester, Manchester, UK
  3. 3Pediatric Immunology-Hematology and Rheumatology Unit, Necker-Enfants Malades Hospital, Assistance Publique-H?pitaux de Paris, Paris, France
  4. 4INSERM UMR 1163, Immunogenetics of Pediatric Autoimmunity, Paris, France
  5. 5Paris Descartes-Sorbonne Paris Cite University, Institute Imagine, Paris, France
  1. Correspondence to Institut Imagine, 24 boulevard du Montparnasse, Paris, 75105, France; yanickcrow{at}mac.com

http://dx.doi.org/10.1136/annrheumdis-2016-210504

Statistics from Altmetric.com

    We read with interest the paper by Konig et al1 describing a novel pathogenic mutation in TMEM173. This report is important in highlighting the stable segregation of a skin-restricted phenotype across four generations, thus expanding the clinical spectrum associated with gain-of-function mutations in stimulator of interferon genes (STING). These authors also report the use of the Janus kinase (JAK)1/3 inhibitor tofacitinib in two of their patients. Unfortunately, since the treatment period was limited to a total of 17 days, it was not possible to draw any conclusions as to therapeutic efficacy. However, we have recently described the use of an alternative JAK(1/2) inhibitor, ruxolitinib, in three STING-mutated patients treated for a period of up to 18 months.2 Importantly, in this study, we observed a marked improvement in all three major …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

    Linked Articles